{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T02:52:21Z","timestamp":1768013541815,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T00:00:00Z","timestamp":1643500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T00:00:00Z","timestamp":1643500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Research Foundation Flanders","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Methusalem financing program of the Flemish Government"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s40273-021-01099-2","type":"journal-article","created":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T16:02:35Z","timestamp":1643558555000},"page":"461-476","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine"],"prefix":"10.1007","volume":"40","author":[{"given":"Zo\u00eb","family":"Pieters","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benson","family":"Ogunjimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Beutels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5720-5291","authenticated-orcid":false,"given":"Joke","family":"Bilcke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,30]]},"reference":[{"key":"1099_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/003591576505800106","volume":"58","author":"RE Hope-Simpson","year":"1965","unstructured":"Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. J R Soc Med. 1965;58:9\u201320. https:\/\/doi.org\/10.1177\/003591576505800106.","journal-title":"J R Soc Med"},{"key":"1099_CR2","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/j.vaccine.2005.09.026","volume":"24","author":"FT Scott","year":"2006","unstructured":"Scott FT, Johnson RW, Leedham-Green M, Davies E, Edmunds WJ, et\u00a0al. The burden of herpes zoster: a prospective population based study. Vaccine. 2006;24:1308\u201314. https:\/\/doi.org\/10.1016\/j.vaccine.2005.09.026.","journal-title":"Vaccine"},{"key":"1099_CR3","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1017\/S0950268811002640","volume":"140","author":"J Bilcke","year":"2012","unstructured":"Bilcke J, Ogunjimi B, Marais C, De Smet F, Callens M, et\u00a0al. The health and economic burden of chickenpox and herpes zoster in Belgium. Epidemiol Infect. 2012;140:2096\u2013109. https:\/\/doi.org\/10.1017\/S0950268811002640.","journal-title":"Epidemiol Infect"},{"key":"1099_CR4","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1503\/cmaj.091711","volume":"182","author":"M Drolet","year":"2010","unstructured":"Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, et\u00a0al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ. 2010;182:1731\u20136. https:\/\/doi.org\/10.1503\/cmaj.091711.","journal-title":"CMAJ"},{"key":"1099_CR5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1017\/S0950268801005921","volume":"127","author":"M Brisson","year":"2001","unstructured":"Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, et\u00a0al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect. 2001;127:305\u201314. https:\/\/doi.org\/10.1017\/S0950268801005921.","journal-title":"Epidemiol Infect"},{"key":"1099_CR6","unstructured":"Belgian Superior Health Council. Vaccination against Herpes Zoster Virus. 2017. https:\/\/www.zorg-en-gezondheid.be\/sites\/default\/files\/atoms\/files\/9209_hgr_advies_zonaa5_pdt.pdf. Accessed 16 Mar 2020."},{"key":"1099_CR7","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/cid\/cis638","volume":"55","author":"KE Schmader","year":"2012","unstructured":"Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, et\u00a0al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 2012;55:1320\u20138. https:\/\/doi.org\/10.1093\/cid\/cis638.","journal-title":"Clin Infect Dis"},{"key":"1099_CR8","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa051016","volume":"352","author":"M Oxman","year":"2005","unstructured":"Oxman M, Levin M, Johnson G, Schmader K, Straus S, et\u00a0al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271\u201384. https:\/\/doi.org\/10.1056\/NEJMoa051016.","journal-title":"N Engl J Med"},{"key":"1099_CR9","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1093\/cid\/ciu918","volume":"60","author":"VA Morrison","year":"2015","unstructured":"Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, et\u00a0al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 2015;60:900\u20139. https:\/\/doi.org\/10.1093\/cid\/ciu918.","journal-title":"Clin Infect Dis"},{"key":"1099_CR10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/S1473-3099(03)00857-0","volume":"4","author":"SL Thomas","year":"2004","unstructured":"Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis. 2004;4:26\u201333. https:\/\/doi.org\/10.1016\/S1473-3099(03)00857-0.","journal-title":"Lancet Infect Dis"},{"key":"1099_CR11","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","volume":"372","author":"H Lal","year":"2015","unstructured":"Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, et\u00a0al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087\u201396. https:\/\/doi.org\/10.1056\/NEJMoa1501184.","journal-title":"N Engl J Med"},{"key":"1099_CR12","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","volume":"375","author":"AL Cunningham","year":"2016","unstructured":"Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, et\u00a0al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375:1019\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1603800.","journal-title":"N Engl J Med"},{"key":"1099_CR13","unstructured":"European Medicines Agency (EMA). Shingrix. 2018. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/shingrix. Accessed 16 Mar 2020."},{"key":"1099_CR14","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria, 2018. https:\/\/www.r-project.org\/. Accessed 13 Dec 2021."},{"key":"1099_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/eLife.07116","volume":"4","author":"B Ogunjimi","year":"2015","unstructured":"Ogunjimi B, Willem L, Beutels P, Hens N. Integrating between-host transmission and within-host immunity to analyze the impact of varicella vaccination on zoster. eLife. 2015;4:1\u201317. https:\/\/doi.org\/10.7554\/eLife.07116.","journal-title":"eLife"},{"key":"1099_CR16","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1177\/0272989X09340585","volume":"29","author":"JJ Barendregt","year":"2009","unstructured":"Barendregt JJ. The half-cycle correction: banish rather than explain it. Med Decis Mak. 2009;29:500\u20132. https:\/\/doi.org\/10.1177\/0272989X09340585.","journal-title":"Med Decis Mak"},{"key":"1099_CR17","unstructured":"Cleemput I, Neyt M, Van de Sande S, Thiry N. Belgian guidelines for economic evaluations and budget impact analyses: second edition. KCE reports 2012; 78C:1-94. D\/2012\/10.273.54. https:\/\/kce.fgov.be\/sites\/default\/files\/page_ documents\/KCE_183_economic_evaluations_second_edition_Report3.pdf. Accessed 12 Mar 2016."},{"key":"1099_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-018-1213-5","volume":"16","author":"PT De Boer","year":"2018","unstructured":"De Boer PT, Van Lier A, De Melker H, Van Wijck AJ, Wilschut JC, et\u00a0al. Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines. BMC Med. 2018;16:1\u201318. https:\/\/doi.org\/10.1186\/s12916-018-1213-5.","journal-title":"BMC Med"},{"key":"1099_CR19","unstructured":"STATBEL. Life expectancy and life tables. 2019. https:\/\/statbel.fgov.be\/en\/themes\/population\/mortality-lifeexpectancy-and-causes-death\/life-expectancy-and-life-tables#panel-12. Accessed 25 Sept 2019."},{"key":"1099_CR20","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1017\/S0950268808000678","volume":"137","author":"A Gauthier","year":"2009","unstructured":"Gauthier A, Breuer J, Carrington D, Martin M, R\u00e9my V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect. 2009;137:38\u201347. https:\/\/doi.org\/10.1017\/S0950268808000678.","journal-title":"Epidemiol Infect"},{"key":"1099_CR21","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/j.vaccine.2008.12.024","volume":"27","author":"AJ van Hoek","year":"2009","unstructured":"van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine. 2009;27:1454\u201367. https:\/\/doi.org\/10.1016\/j.vaccine.2008.12.024.","journal-title":"Vaccine"},{"key":"1099_CR22","unstructured":"Bilcke J, Marais C, Ogunjimi B, Van Hoek AJ, Lejeune O, et\u00a0al. Cost-utility of vaccination against chickenpox in children and against herpes zoster in elderly in Belgium. Tech. rep. Brussels: Belgian Health Care Knowledge Centre (KCE); 2011."},{"key":"1099_CR23","unstructured":"The World Bank Indicators. GDP deflator (base year varies by country)-Belgium. 2020. https:\/\/data.worldbank.org\/indicator\/NY.GDP.DEFL.ZS?locations=BE. Accessed 21 Apr 2020."},{"key":"1099_CR24","unstructured":"National Sickness Fund. General practitioner: Price consultations 2020. 2020. https:\/\/www.cm.be\/diensten-en-voordelen\/ziekte-en-behandeling\/terugbetalingen-behandelingen\/huisartsen\/raadplegingen. Accessed 21 Feb 2020."},{"key":"1099_CR25","unstructured":"Rijksinstituut voor ziekte-en invaliditeitsverzekering (RIZIV). Honoraria, prijzen en tegemoetkoming van artsen-Raadplegingen en bezoeken. 2020. https:\/\/www.riziv.fgov.be\/SiteCollectionDocuments\/tarief_artsen_deel01_20200314.pdf. Accessed 05 July 2020."},{"key":"1099_CR26","unstructured":"Belgian Center for Pharmacotherapeutic Information. Vaccin against Zona. 2019. https:\/\/www.bcfi.be\/nl\/chapters\/13?frag=20636. Accessed 07 Nov 2019."},{"key":"1099_CR27","unstructured":"Centers for Disease Control and Prevention. CDC Vaccine price List. 2020. https:\/\/www.cdc.gov\/vaccines\/programs\/vfc\/awardees\/vaccinemanagement\/price-list\/index.html. Accessed 22 Apr 2020."},{"key":"1099_CR28","unstructured":"Berete F, Tafforeau J, Demarest S, Drieskens S. Vaccinatie: Gezondheid530 senqu\u00eate 2018. Tech. rep. Brussels: Sciensano, 2018. https:\/\/his.wiv-isp.be\/nl\/Gedeelde%20%20documenten\/HES_NL_2018.pdf. Accessed 13 Dec 2021."},{"key":"1099_CR29","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1016\/j.vaccine.2011.09.079","volume":"30","author":"J Bilcke","year":"2012","unstructured":"Bilcke J, Ogunjimi B, Hulstaert F, Van Damme P, Hens N, et\u00a0al. Estimating the age-specific duration of herpes zoster vaccine protection: a matter of model choice? Vaccine. 2012;30:2795\u2013800. https:\/\/doi.org\/10.1016\/j.vaccine.2011.09.079.","journal-title":"Vaccine"},{"key":"1099_CR30","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/infdis\/jiv480","volume":"213","author":"MJ Levin","year":"2016","unstructured":"Levin MJ, Schmader KE, Pang L, Williams-Diaz A, Zerbe G, et\u00a0al. Cellular and humoral responses to a second dose of herpes zoster vaccine administered 10 years after the first dose among older adults. J Infect Dis. 2016;213:14\u201322. https:\/\/doi.org\/10.1093\/infdis\/jiv480.","journal-title":"J Infect Dis"},{"key":"1099_CR31","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1177\/0272989X20937253","volume":"40","author":"Z Pieters","year":"2020","unstructured":"Pieters Z, Strong M, Pitzer VE, Beutels P, Bilcke J. A computationally efficient method for probabilistic parameter threshold analysis for health economic evaluations. Med Decis Mak. 2020;40:669\u201379. https:\/\/doi.org\/10.1177\/0272989X20937253.","journal-title":"Med Decis Mak"},{"key":"1099_CR32","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.vaccine.2011.10.036","volume":"30","author":"J Bilcke","year":"2012","unstructured":"Bilcke J, Marais C, Ogunjimi B, Willem L, Hens N, et\u00a0al. Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium. Vaccine. 2012;30:675\u201384. https:\/\/doi.org\/10.1016\/j.vaccine.2011.10.036.","journal-title":"Vaccine"},{"key":"1099_CR33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/jmv.10316","volume":"70","author":"FT Scott","year":"2003","unstructured":"Scott FT, Leedham-Green ME, Barrett-Muir WY, Hawrami K, Gallagher WJ, et\u00a0al. A study of shingles and the development of postherpetic neuralgia in east London. J Med Virol. 2003;70:25\u20139. https:\/\/doi.org\/10.1002\/jmv.10316.","journal-title":"J Med Virol"},{"key":"1099_CR34","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1080\/21645515.2017.1345399","volume":"13","author":"D Curran","year":"2017","unstructured":"Curran D, Van Oorschot D, Varghese L, Oostvogels L, Mrkvan T, et\u00a0al. Assessment of the potential public health impact of herpes zoster vaccination in Germany. Hum Vaccines Immunother. 2017;13:2213\u201321. https:\/\/doi.org\/10.1080\/21645515.2017.1345399.","journal-title":"Hum Vaccines Immunother"},{"key":"1099_CR35","doi-asserted-by":"publisher","first-page":"E932","DOI":"10.1503\/cmaj.190274","volume":"191","author":"M Drolet","year":"2019","unstructured":"Drolet M, Zhou Z, Sauvageau C, DeWals P, Gilca V, et\u00a0al. Effectiveness and cost-effectiveness of vaccination against herpes zoster in Canada: a modelling study. CMAJ. 2019;191:E932\u20139. https:\/\/doi.org\/10.1503\/cmaj.190274.","journal-title":"CMAJ"},{"key":"1099_CR36","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/21645515.2018.1509645","volume":"15","author":"D Van Oorschot","year":"2019","unstructured":"Van Oorschot D, Anastassopoulou A, Poulsen NB, Varghese L, von Krempelhuber A, Neine M, et\u00a0al. Cost-effectiveness of the recombinant zoster vaccine in the German population aged $$\\ge 60$$ years old. Hum Vaccines Immunother. 2019;15:34\u201344. https:\/\/doi.org\/10.1080\/21645515.2018.1509645.","journal-title":"Hum Vaccines Immunother"},{"key":"1099_CR37","doi-asserted-by":"publisher","first-page":"5037","DOI":"10.1016\/j.vaccine.2018.07.005","volume":"36","author":"D Curran","year":"2018","unstructured":"Curran D, Patterson B, Varghese L, Van Oorschot D, Buck P, et\u00a0al. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States. Vaccine. 2018;36:5037\u201345. https:\/\/doi.org\/10.1016\/j.vaccine.2018.07.005.","journal-title":"Vaccine"},{"key":"1099_CR38","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s40258-019-00491-6","volume":"17","author":"A McGirr","year":"2019","unstructured":"McGirr A, Van Oorschot D, Widenmaier R, Stokes M, Ganz ML, et\u00a0al. Public health impact and cost-effectiveness of non-live adjuvanted recombinant zoster vaccine in Canadian adults. Appl Health Econ Health Policy. 2019;17:723\u201332. https:\/\/doi.org\/10.1007\/s40258-019-00491-6.","journal-title":"Appl Health Econ Health Policy"},{"key":"1099_CR39","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1001\/jamainternmed.2017.7431","volume":"178","author":"P Le","year":"2018","unstructured":"Le P, Rothberg MB. Cost-effectiveness of the adjuvanted herpes zoster subunit vaccine in older adults. JAMA Internal Med. 2018;178:248\u201358. https:\/\/doi.org\/10.1001\/jamainternmed.2017.7431.","journal-title":"JAMA Internal Med"},{"key":"1099_CR40","doi-asserted-by":"publisher","first-page":"380","DOI":"10.7326\/M18-2347","volume":"170","author":"LA Prosser","year":"2019","unstructured":"Prosser LA, Harpaz R, Rose AM, Gebremariam A, Guo A, et\u00a0al. A cost-effectiveness analysis of vaccination for prevention of herpes zoster and related complications: input for national recommendations. Ann Internal Med. 2019;170:380\u20138. https:\/\/doi.org\/10.7326\/M18-2347.","journal-title":"Ann Internal Med"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-021-01099-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-021-01099-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-021-01099-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T18:06:19Z","timestamp":1664215579000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-021-01099-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,30]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1099"],"URL":"https:\/\/doi.org\/10.1007\/s40273-021-01099-2","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,30]]},"assertion":[{"value":"30 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"P.B. and J.B. conceived the study. Z.P. performed the analyses and wrote the first draft. B.O. commented on the choices made in the input data. All authors read and approved the final version for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"This work was supported in part by Research Foundation-Flanders (JB), the Methusalem financing program of the Flemish government (ZP). The funding agreements ensured the authors\u2019 independence in designing the study, interpreting the data, and writing and publishing the report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"In 2019, P.B. participated in four half-day meetings organised by Pfizer Belgium. These meetings led to the development of a summary paper that was published in 2020 (Annemans et\u00a0al., Value in Health 2020). For his participation, the University of Antwerp received compensation. P.B. received no personal fee for his participation. The University of Antwerp received grant money from the European Commission\u2019s IMI programme (RESCEU; 2017\u20132021) to fund research on RSV conducted in The Centre for Health Economics Research & Modelling Infectious Diseases (CHERMID), which P.B. heads. The IMI programme involves many pharmaceutical companies in a public\u2013private partnership. CHERMID also collaborated with the Centre for the Evaluation of Vaccination on a study on pneumococcal carriage in children (2015\u20132019), and that study was supported by a grant from Pfizer. In the period 2009\u20132019, the University of Antwerp received for its part-time \u201cchair in evidence-based vaccinology\u201d unrestricted grants from Pfizer and GSK. P.B. is promotor of the chair, but not the chair holder. By definition, the research agenda supported by the chair holder is determined and executed completely independent from the sponsors. The chair is no longer supported by private sponsors since January 2020.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for participate"}},{"value":"All data are presented within the main text or Appendix. Data files are also implemented in the R model, which is available upon request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The R code is available upon request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}